Paradigm Biocapital Advisors LP 13D and 13G filings for Tarsus Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 4:35 pm Purchase | 2024-09-30 | 13G | Tarsus Pharmaceuticals, Inc. TARS | Paradigm Biocapital Advisors LP | 2,440,445 6.400% | 512,939 (+26.61%) | Filing |
| 2024-01-22 5:05 pm Purchase | 2024-01-12 | 13G | Tarsus Pharmaceuticals, Inc. TARS | Paradigm Biocapital Advisors LP | 1,927,506 5.800% | 1,927,506 (New Position) | Filing |